Prednisone
- Generic Name
- Prednisone
- Brand Names
- Deltasone, Rayos, Winpred
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26O5
- CAS Number
- 53-03-2
- Unique Ingredient Identifier
- VB0R961HZT
- Background
A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.
Prednisone was granted FDA approval on 21 February 1955.
- Indication
Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.
- Associated Conditions
- Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis
- Associated Therapies
- Palliative Treatment
Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-10-31
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Fondazione EMN Italy Onlus
- Target Recruit Count
- 402
- Registration Number
- NCT00551928
- Locations
- 🇮🇹
Division of Hematology, AOU Città della Salute e della Scienza di Torino, Torino, Italy
Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia
Not Applicable
- Conditions
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- Dutch Childhood Oncology Group
- Target Recruit Count
- 445
- Registration Number
- NCT00550992
- Locations
- 🇨🇿
University Hospital Motol, Prague, Czechia
🇫🇷CHR Hotel Dieu, Nantes, France
🇺🇸Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States
A Study of NeoRecormon (Epoetin Beta), CellCept (Mycophenolate Mofetil) and Prednisone in Patients With Low or Intermediate Myelodysplastic Syndromes.
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2016-07-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 10
- Registration Number
- NCT00551291
An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma
- First Posted Date
- 2007-10-16
- Last Posted Date
- 2014-07-17
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 57
- Registration Number
- NCT00544440
PET Scans in Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-10-16
- Last Posted Date
- 2019-05-15
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 156
- Registration Number
- NCT00544219
- Locations
- 🇨🇭
Kantonspital Aarau, Aarau, Switzerland
🇨🇭Kantonsspital Bruderholz, Bruderholz, Switzerland
🇨🇭Kantonsspital Liestal, Liestal, Switzerland
Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-10-10
- Last Posted Date
- 2009-10-27
- Target Recruit Count
- 150
- Registration Number
- NCT00541281
- Locations
- 🇧🇪
Parc Léopold, Brussels, Belgium
🇧🇪Sint Nilolaus, Eupen, Belgium
🇧🇪CH Jolimont Lobbes, La-Louvière, Belgium
Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2016-06-21
- Lead Sponsor
- Attaya Suvannasankha
- Target Recruit Count
- 70
- Registration Number
- NCT00540644
- Locations
- 🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States
A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN)
- First Posted Date
- 2007-10-05
- Last Posted Date
- 2020-09-17
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT00539838
An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-10-01
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 131
- Registration Number
- NCT00537381
LAL-BR/2001: Study Treatment to Low Risk ALL
Phase 4
Completed
- Conditions
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2016-01-20
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 150
- Registration Number
- NCT00526175
- Locations
- 🇪🇸
Basurtuko Ospitalea, Basurto, Spain
🇪🇸Complejo Hospitalario Universitario de Albacete, Albacete, Spain
🇪🇸Hospital General de Alicante, Alicante, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath